A survey of palivizumab for infants with cystic fibrosis in the UK

• Published in: Archives of disease in childhood Vol. 92; no. 1; pp. 87 - 88
• Main Authors: McCormick, J, Southern, K W
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health 01.01.2007; BMJ Publishing Group Ltd; BMJ Publishing Group LTD; BMJ Group
• Subjects: Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Antiviral Agents - therapeutic use; Cohort Studies; Cystic fibrosis; Cystic Fibrosis - complications; Funding; Health Care Surveys; Humans; Infant; Infant, Newborn; Infections; Letters; Lung diseases; Medical screening; Monoclonal antibodies; Mortality; Palivizumab; Pathogenesis; Prevention; Prophylaxis; Respiratory Syncytial Virus Infections - mortality; Respiratory Syncytial Virus Infections - prevention & control; United Kingdom - epidemiology; United Kingdom; United Kingdom > UK
• ISSN: 0003-9888; 1468-2044
• DOI: 10.1136/adc.2006.0105338

Of these, 70 infants were diagnosed by newborn screening (48.6%); 16 (11.2%) of the 143 infants were hospitalised owing to RSV infection; none required paediatric intensive care unit admission and none died; 14 (9.8%) infants received palivizumab between three cystic fibrosis centres, and one of these infants was subsequently hospitalised with RSV infection (other risk factors for this infant were not reported).